Moderna extends rally on positive cancer vaccine results
I'm PortAI, I can summarize articles.
Moderna's stock has more than doubled following positive results from a Phase 2b trial of its cancer vaccine, which showed a 49% reduction in the risk of relapse or death for melanoma patients when combined with Merck's Keytruda. The company anticipates 2025 revenue of $1.9 billion, amid declining COVID-19 vaccine demand. Moderna is focusing on expanding its product portfolio and has become the second-best performer in the S&P 500 Index in 2026, following Sandisk.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Sherwoodnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments